Hoth Therapeutics

186 articles about Hoth Therapeutics

• Hoth Therapeutics Expands Research Collaboration Agreement with Weill Cornell Medicine to Continue the Advancement of HT-003 for Acne Treatment Research

  1/28/2021

  Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("HOTH" or the "Company"), a biopharmaceutical company, today announced extending a research collaboration agreement with Weill Cornell Medicine to continue investigating the therapeutic mechanism of action and safety of HT-003, a novel retinoic acid metabolism blocking agent (RAMBA), for the treatment of acne.

• Hoth Therapeutics Announces the Appointment of Mario E. Lacouture, M.D. to Oversee Dermatology Therapeutic Program for Cancer Patients as Part of Hoth Scientific Advisory Board

  1/27/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), ("Hoth" or the "Company"), a biopharmaceutical company, today announced the addition of Mario Lacouture, M.D. to the Company's Scientific Advisory Board.

• Hoth Therapeutics Announces Positive Initial Mechanism of Action Data for HT-003 In Pursuit for Acne Treatment Indication

  1/20/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced new in vitro data demonstrating the therapeutic potential of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

• FDA Grants Hoth Therapeutics Pre-IND Meeting Regarding Proposed Drug Development Plan for HT-001 Treatment for Cancer Patients

  1/13/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the Pre-IND meeting requested on 22 December 2020 for HT-001 with the U.S. Food and Drug Administration (FDA) Division of Dermatology and Dental Products has been granted to receive written responses only from FDA that are targeted for delivery on F

• Hoth Therapeutics to Initiate IND Enabling Studies of HT-001 Treatment for Cancer Patients

  1/11/2021

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced an agreement with Charles River Laboratories to initiate preclinical studies of HT-001 , a topical formulation designed for the treatment of patients with rash and skin disorders associated with initial and repeat EGFR inhibitor cancer treatment.

• Hoth Therapeutics Announces Private Placement of Equity Priced At-The-Market Under Nasdaq Rules

  1/5/2021

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to institutional investors.  Upon the closing of the financing,

• Hoth Therapeutics Announces Licensing Agreement and Collaboration with U.S. Army Medical Research and Development Command (USAMRDC) for Treating Multi-Drug Resistant Bacterial Lung Infections

  1/4/2021

  License Covers Novel Molecular Entity Developed by the Walter Reed Army Institute of Research The HT-006 active pharmaceutical ingredient is expected to be a broad-spectrum antibiotic for treatment of serious bacterial infections of the lung

• Hoth Therapeutics Announces Production of HT-001 for Cancer Treatment

  12/31/2020

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that it has signed a production agreement for both GLP and GMP materials associated with HT-001  with Tergus Pharma for its novel cancer treatment drug, HT-001.

• Hoth Therapeutics Submits Request for a Pre-Investigational New Drug (Pre-IND) Meeting for HT-001, Treatment for Cancer Patients

  12/23/2020

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced the request for a Pre-Investigational New Drug (IND) meeting to the U.S. Food and Drug Administration (FDA) to discuss the proposed drug development program for HT-001, a topical drug formation under development for the treatment of rash and skin disord

• Hoth Therapeutics Receives Approval to Commence Phase 1b Clinical Trial of BioLexa for the Treatment of Atopic Dermatitis in Humans

  12/10/2020

   Hoth Therapeutics, Inc. (NASDAQ:  HOTH ), a biopharmaceutical company, today announced that is has received Human Research Ethics Committee (HREC) clearance to commence the first cohort of the Phase 1b clinical trial of BioLexa  Lotion for the treatment of mild to moderate atopic dermatitis in Australia. 

• Hoth Therapeutics Announces Positive, Statistically Significant Proof-of-Concept Preclinical Data on its Therapeutic for Cutaneous Lupus Erythematosus (CLE), a Chronic Autoimmune Skin Disease

  11/3/2020

  The study was conducted by Jackson Laboratory in partnership with Zylö Therapeutics The animal study supports that this drug candidate has the potential to be an effective treatment for cutaneous manifestations of lupus, a significant unmet medical need

• Hoth Therapeutics Provides Update for Novel COVID-19 Therapeutic, On-the-Go SARS-CoV-2 Testing Device, and Vaccine

  11/2/2020

  Hoth Therapeutics expects key proof-of-concept data in Q4 2020 / Q1 2021 for its COVID-19 products it is currently developing

• Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic

  10/20/2020

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company , today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademar

• Hoth Therapeutics Announces its HT-003 Shows Positive Initial Data Inhibiting Toll-like Receptor 2 (TLR2)

  9/24/2020

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced completing testing to examine the ability of HT-003 to block acne pathogenic gene expression in human keratinocytes, the major cell type of the epidermis and the outermost of the layers of the skin.

• Hoth Therapeutics Enters into Sponsored Research Agreement for On-the-Go COVID-19 Testing Device

  9/21/2020

  Hoth Therapeutics announced  that it has entered into a Sponsored Research Agreement ("SRA") with the George Washington University ("GW") relating to the development of an in vitro diagnostic device that has the potential for testing by patients anywhere to allow public health professionals to immediately detect SARS-CoV-2 via a mobile device as an aid in the diagnosis of the COVID-19 infection.

• 

  Biopharma Update on the Novel Coronavirus: September 21

  9/21/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for September 21, 2020.

• Hoth Therapeutics' Chief Scientific Officer, Dr. Stefanie Johns, to Appear on One America News Network on Tuesday, September 1, 2020

  9/1/2020

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced  Dr. Stefanie Johns, who has agreed to join Hoth and serve as its Chief Scientific Officer, is scheduled to appear as a featured guest on One America News Network Tuesday, September 1, 2020 at 3:00pm ET.

• Hoth Therapeutics Appoints Stefanie Johns, Ph.D., as Chief Scientific Officer

  8/31/2020

  Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020 . In her role, Dr. Johns will further advance Hoth's pipeline through both preclinical and clinical stages. 

• Hoth Therapeutics Announces Participation at Upcoming Investor Conferences in September

  8/28/2020

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Chief Executive Officer, Robb Knie, is scheduled to present at the following investor conferences in September: T

• Hoth Therapeutics Provides Shareholder Update on COVID-19 Initiatives and Dermatological Therapy Pipeline

  8/19/2020

  Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today is providing shareholders with a update on its COVID-19 initiatives including vaccine and real-time, breath-based mobile testing device  as well as its dermatological therapy pipeline.